ReviewCurrent hypertension reports2004
Assessment of cardiovascular risk and choice of antihypertensive therapy.
Review in Current hypertension reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prediction of Prehypertenison and Hypertension Based on Anthropometry, Blood Parameters, and Spirometry.International journal of environmental research and public health · 2018Article
- The Effects of Aqueous Extract fromEvidence-based complementary and alternative medicine : eCAM · 2017Article
- Individualization of antihypertensive drug treatment.Diabetes care · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Indications, choices of therapy, and goals of treatment for hypertension should be closely linked to the multivariate risk of cardiovascular events and ingredients of the vascular risk profile of patients with hypertension. Hypertension commonly occurs in combination with other cardiovascular disease risk factors, and the burden of the associated risk factors greatly affects the impact of elevated blood pressure and usually requires choices of specific antihypertensive agents shown to be particularly efficacious in the context of the associated risk factors or vascular conditions present. Guidelines assign highest priority to rigorous control of the blood pressure. Risk associated with hypertension has been shown to be incremental, with the level of blood pressure extending down to what was formerly considered the high-normal blood pressure range. In this "prehypertensive" state, drug treatment is justified only if the multivariate risk is substantial or there is target-organ damage. Most individuals with the metabolic syndrome, a condition commonly associated with hypertension, and singled out as an important consideration for treatment, are usually identified by the Framingham multivariate risk formulation. They require weight control and exercise, as well as specific choices of antihypertensive agents.
Indexed as
Identifiers
15341685What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.